“This shows shareholders we have had four parties go through every drawer, turn over every leaf and still sign on that bottom line,” said Webster,
“The difference between what we and Neuren have done is we both got partners earlier which supports development all the way through, whereas Opthea didn’t have any partners at all,” Webster said.
She said Dimerix had not experienced any setbacks or problems with the FDA, despite US President Donald Trump’s staffing cuts to the regulator.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.035(6.25%) |
Mkt cap ! $308.6M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 57.0¢ | 52.0¢ | $1.033M | 1.931M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18732 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 30517 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| DXB (ASX) Chart |